BSEGeneral2 Nov 2026 · 2 Nov 2026, 08:58 pm
Clarification regarding news report relating to the Company''s Assam facility
Sun Pharmaceutical Industries Ltd · 524715
✦ AI SummaryRegulatory
Sun Pharmaceutical Industries Ltd clarified a news report regarding quality lapses at its Assam facility, stating the issue occurred in August 2026 and was not considered material at the time. The company also announced its financial results for the quarter and half year ended 30 September 2026 on 30 October 2026.
Analysis Scores
Earnings Impact5/10
Growth Catalyst2/10
Governance Concern1/10
Regulatory Risk6/10
Balance Sheet Risk1/10
Liquidity Impact8/10
Market Sentiment5/10
✦ Ask a Question
Ask anything about this announcement — AI will answer based on the filing content.
Full Announcement
Sun Pharmaceutical Industries Ltd - 524715 - Rumour verification - Regulation 30(11)
Attachments (1)
📄pdf
Download →
1bbe06aa-8721-4e47-b0b1-985a91279ce9.pdf
View document text
Sun Pharmaceutical Industries Limited
Sun House, Plot No. 201 B/1,
Western Express Highway, Goregaon (E),
Mumbai – 400 063, Maharashtra, INDIA.
Tel.: (91-22) 4324 4324
Fax: (91-22) 4324 4343
Website: www.sunpharma.com
Email: secretarial@sunpharma.com
CIN: L24230GJ1993PLC019050
02 November 2026
BSE Limited National Stock Exchange of India Limited
Phiroze Jeejeebhoy Towers Exchange Plaza, Bandra Kurla Complex
Dalal Street, Mumbai – 400 001 Bandra (East), Mumbai – 400 051
BSE Code: 524715 NSE Code: SUNPHARMA
Subject: Clarification regarding news report relating to the Company’s Assam facility
Dear Sir/Madam,
This is with reference to the communications received from the Stock Exchanges seeking clarification on the
news report dated 30 October 2026 captioned “India orders Sun Pharma to halt eye-care drug production at
plant after quality lapses” (“News Report”) and the movement in the price of the Company’s shares.
In this regard, Sun Pharmaceutical Industries Limited (“Company”) submits as follows:
The News Report relates to developments that occurred in August 2026 and does not concern any new event or
development occurring on 30 October 2026. The matter was assessed at the relevant time and was not considered
to warrant a disclosure under Regulation 30 of the SEBI Listing Regulations.
As regards the share price movement, it may also be noted that the Company announced its financial results for
the quarter and half year ended 30 September 2026 on 30 October 2026. The Company is not in a position to
attribute the movement in its share price to the News Report or to any particular factor.
The Company further confirms that it is not aware of any material event or information requiring disclosure
under Regulation 30 that has not been disclosed to the Stock Exchanges and that could explain the aforesaid
movement in the price of its shares.
Thank you.
For Sun Pharmaceutical Industries Limited
(Anoop Deshpande)
Company Secretary and Compliance Officer
ICSI Membership No.: A23983
Registered Office: SPARC, Tandalja, Vadodara – 390 012, Gujarat, INDIA.
Reaching People. Touching Lives.